Abstract
We conducted an open-labeled clinical trial of interferon beta-1b (IFNB) treatment in 20 patients with primary progressive multiple sclerosis (PPMS) and longitudinally monitored autoantibodies against double-stranded DNA (dsDNA), thyroid peroxidase (TPO),myelin basic protein (MBP), myelin oligodendrocyte glycoprotein (MOG), synapsin and S-100B. Before treatment, one patient had elevated TPO antibodies, four patients had elevated antibodies against S-100B, two patients against MOG or synapsin and one patient against MBP. In two patients we observed a continuous increase of dsDNA or TPO antibodies above the normal range. This rise paralleled IFNB treatment. In addition, 11 of 20 patients developed neutralizing antibodies against IFNB. There was no increase of autoantibodies directed against central nervous system antigens. Like patients with relapsing remitting or secondary progressive multiple sclerosis, PPMS patients may be at risk of an autoimmune response during IFNB treatment.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bendtzen K (2003) Anti-IFN BAb and NAb antibodies: a minireview. Neurology 61:S6–S10
Dahlke F, Graf R, Beckmann K, Kappos L, Polman CH, Pozzilli C, Thompson AJ, European Study Group on IFNB-1b in SP-MS (2000) Twenty-Four months follow-up of hepatic, thyroid, and other autoimmune parameters in patients with secondary progressive multiple sclerosis (SP-MS) on 8 MIU interferon beta-1b (IFNB-1b) or placebo s. c. in a double-blind placebo-controlled multicenter study. Neurology 54(Suppl 3):A338
Durelli L, Ferrero B, Oggero A, Verdun E, Bongioanni MR, Gentile E, Isoardo GL, Ricci A, Rota E, Bergamasco B, Durazzo M, Saracco G, Biava MA, Brossa PC, Giorda L, Pagni R, Aimo G (1999) Autoimmune events during interferon beta-1b treatment for multiple sclerosis. J Neurol Sci 162:74–83
The IFNB Multiple Sclerosis Study Group (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. Clinical results of a multicenter, randomized, double-blind, placebo-controlled study. Neurology 43:655–661
Kawade Y (1980) An analysis of neutralization reaction of interferon by antibody: a proposal on the expression of neutralization titer. J Interferon Res 1:61–70
Leary SM, Miller DH, Stevenson VL, Brex PA, Chard DT, Thompson AJ (2003) Interferon beta-1a in primary progressive MS: an exploratory, randomized, controlled trial. Neurology 60:44–51
Monzani F, Caraccio N, Meucci G, Lombardo F, Moscato G, Casolaro A, Ferdeghini M, Murri L, Ferrannini E (1999) Effect of 1-year treatment with interferon-beta1b on thyroid function and autoimmunity in patients with multiple sclerosis. Eur J Endocrinol 141:325–331
Niederwieser G, Buchinger W, Bonelli RM, Berghold A, Reisecker F, Koltringer P, Archelos JJ (2003) Prevalence of autoimmune thyroiditis and non-immune thyroid disease in multiple sclerosis. J Neurol 250:672–675
Rotondi M, Mazziotti G, Biondi B, Manganella G, Del Buono AD, Montella P, di Cristofaro M, Di Iorio G, Amato G, Carella C (2000) Long-term treatment with interferon-beta therapy for multiple sclerosis and occurrence of Graves’ disease. J Endocrinol Invest 23:321–324
Sadatipour BT, Greer JM, Pender MP (1998) Increased circulating antiganglioside antibodies in primary and secondary progressive multiple sclerosis. Ann Neurol 44:980–983
Schlaf G, Salje C, Wetter A, Stuertz K, Felgenhauer K, Mäder M (1998) Determination of synapsin I and synaptophysin in body fluids by two-site enzyme-linked immunosorbent assays. J Immunol Methods 213:191–199
Spadaro M, Amendolea MA, Mazzucconi MG, Fantozzi R, Di Lello R, Zangari P, Masala G (1999) Autoimmunity in multiple sclerosis: study of a wide spectrum of autoantibodies. Mult Scler 5:121–125
Speciale L, Saresella M, Caputo D, Ruzzante S, Mancuso R, Calvo MG, Guerini FR, Ferrante P (2000) Serum auto antibodies presence in multiple sclerosis patients treated with beta-interferon 1a and 1b. J Neurovirol 6(Suppl 2):S57–S61
Thompson AJ, Montalban X, Barkhof F, Brochet B, Filippi M, Miller DH, Polman CH, Stevenson VL, McDonald WI (2000) Diagnostic criteria for primary progressive multiple sclerosis: a position paper. Ann Neurol 47:831–835
Verdun E, Isoardo G, Oggero A, Ferrero B, Ghezzi A, Montanari E, Zaffaroni M, Durelli L (2002) Autoantibodies in multiple sclerosis patients before and during IFN-beta 1b treatment: are they correlated with the occurrence of autoimmune diseases? J Interferon Cytokine Res 22:245–255
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Bitsch, A., Dressel, A., Meier, K. et al. Autoantibody synthesis in primary progressive multiple sclerosis patients treated with interferon beta-1b. J Neurol 251, 1498–1501 (2004). https://doi.org/10.1007/s00415-004-0580-3
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s00415-004-0580-3